A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China
Home » A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China
2022
Jiang Q, Li Z, Qin Y, Hu Y, Li W, Liu X, Xu N, Zhang Y, Song Y, Meng L, Hong Z, Liu B, Li Y, Chen S, Xue M, Zhu H, Li H, Du X, Lou J, Zhang X, Liang Y, Dai YJ, Chen Z, Niu Q, Men L, Yang D, Zhai Y, Huang XJ. A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China. Blood. [Oral presentation presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. vol. 140 no. (suppl 1):, pp. 198-199, doi: 10.1182/blood-2022-170868